Clinical trials: Migraine in Children
- Condition Migraine in Children
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Migraine
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment…
- Trial name
- NCT04530110
- Testing
- Fremanezumab
- Where
- 70 sites in United States, Canada and 7 more
- Volunteers
- 499 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Migraine Disorders, Headache Disorders
Therapy for Migraine Prevention in Children 6-11 Years of Age
The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in pediatric patients 6 to 11 years old.
- Trial name
- NCT04050293
- Testing
- SPN-538
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.
- Trial name
- OASIS(CM) (NCT03832998)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 284 people
- Sponsor
- Amgen
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
- Trial name
- NCT01662492
- Testing
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents
Migraine in children and adolescents can be associated with low serum levels of coenzyme q10, the key-enzyme of mitochondrial energy production.During migraine attacks inflammation is an important issue.
- Trial name
- NCT01010711
- Testing
- Migra 3
- Where
- 2 sites in Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Complen Health GmbH
Migraine in Children
A Survey Study to Assess the Accessibility of the Nerivio Device At School
This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in the school setting.
- Trial name
- NCT06180577
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Theranica
Chronic Migraine in Children
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
- Trial name
- PROSPECT-2 (NCT04965675)
- Testing
- Eptinezumab
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 285 people
- Sponsor
- H. Lundbeck A/S
Drug Resistant Epilepsy, Autism Spectrum Disorder
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
- Conditions
- Drug Resistant Epilepsy, Autism Spectrum Disorder, Chronic Migraine, Brain Tumor, Pediatric
- Trial name
- NCT06309251
- Testing
- ketogenic diet (as per clinical practice)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Danone Nutricia SpA Società Benefit
Migraine
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with…
- Trial name
- NCT03988088
- Testing
- Lasmiditan
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Migraine Disorders
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
- Trial name
- NCT04748601
- Testing
- Qudexy XR
- Where
- 15 sites in United States
- Volunteers
- 132 people
- Sponsor
- Upsher-Smith Laboratories
Migraine
AMG 334 20160172 Pediatric Migraine PK Study.
AMG 334 20160172 Pediatric Migraine PK Study.
- Trial name
- NCT03499119
- Testing
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- Amgen
Acute Migraine With or Without Aura in Adolescents
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17…
- Trial name
- NCT01004263
- Testing
- rizatriptan benzoate
- Volunteers
- 674 people
- Sponsor
- Organon and Co
Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
- Trial name
- NCT05156398
- Testing
- Rimegepant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 640 people
- Sponsor
- Pfizer
Migraine, Vascular Headaches
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the prevention of migraine attacks in children (12 to 17 years of age).
- Trial name
- NCT00210535
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine in Children, Migraine
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
- Trial name
- NCT04537429
- Testing
- Eptinezumab
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- H. Lundbeck A/S
Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17.
- Trial name
- PIONEER-PEDS2 (NCT04396574)
- Testing
- Lasmiditan
- Where
- 134 sites in United States, Belgium and 13 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine.
- Trial name
- REBUILD-1 (NCT03432286)
- Testing
- Galcanezumab
- Where
- 73 sites in United States, Denmark and 8 more
- Volunteers
- 533 people
- Sponsor
- Eli Lilly and Company
Primary Headache Disorder
Feasibility of a Developmentally-tailored Mobile App for Tracking Mood and Pain in Children With Migraine
This study aims to inform the continued development of a mobile app intended to support the treatment of CYP with migraine. After extensive public and patient involvement, Happyr Health has developed a mobile app that allows…
- Trial name
- NCT05337930
- Testing
- Happyr App
- Where
- United Kingdom
- Sponsor
- Happyr Ltd